UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 Or 15(D) of The
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 29, 2003
ANTARES PHARMA, INC.
---------------------
(Exact Name of Registrant as Specified in Charter)
Minnesota 0-20945 41-1350192
--------- ------- ----------
(State or Other (Commission (I.R.S. Employer
Jurisdiction File Number) Identification No.)
of Incorporation)
707 Eagleview Boulevard, Suite 414, Exton, PA 19341
--------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (610) 458-6200
Not Applicable
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Item 9. Regulation FD Disclsoure.
On May 29, 2003, Antares Pharma, Inc. issued a press release regarding its
presentation at the Friedman Billings Ramsey 7th Annual Technology and Growth
Investor Conference. A copy of the press release issued is attached hereto as
Exhibit 99.1
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
99.1 Press Release dated May 29, 2003.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: May 29, 2003 ANTARES PHARMA, INC.
By /s/ Lawrence M. Christian
----------------------------
Lawrence M. Christian
Chief Financial Officer
EXHIBIT INDEX
99.1 Press Release dated May 29, 2003.